Type 2 diabetes mellitus
Conditions
Interventions
24Weeks Lixisenatide 20ug once daily+Glargine/Detemir once daily
24Weeks Lixisenatide 10ug once daily+Glargine/Detemir once daily
Sponsors
Kitano Hospital, The Tazuke Kofukai Medical Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with type 2 diabetes who are injecting basal insulin (glargine or detemir) or premixed insulin SID or BID. 2. Age >20 years old
Exclusion criteria
Exclusion criteria: 1. The patients who did not agree with this study 2. The patients with serious complications 3. The patients who are at high risk for hypoglycemia 4. The patients who have the history of severe hypoglycemia (needed an emergency transport according to the hypoglycemia unawareness) 5. Those who are not approved to be eligible to this study by corresponding researcher or co-researchers
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Changes in blood glucose levels (average, SD value, MAGE value), HbA1c, body weight, and frequency of hypoglycemia at 4, 8, 12 and 24 weeks. | — |
Primary
| Measure | Time frame |
|---|---|
| Changes in daily insulin dose of insulin glargine at 12 and 24 weeks | — |
Countries
Japan
Contacts
Public ContactYoshiyuki Hamamoto
Kitano Hospital, The Tazuke Kofukai Medical Research Institute Center for Diabetes and Endocrinology
Outcome results
None listed